IRADIMED CORPORATION (FRA:46K)
Germany · Delayed Price · Currency is EUR | Market Cap | 979.96M +15.3% |
| Revenue (ttm) | 75.57M +11.2% |
| Net Income | 20.18M +11.6% |
| EPS | 1.60 +11.2% |
| Shares Out | n/a |
| PE Ratio | 48.51 |
| Forward PE | 36.18 |
| Dividend | 1.09 (1.40%) |
| Ex-Dividend Date | Aug 14, 2026 |
| Volume | 3 |
| Open | 77.50 |
| Previous Close | 77.50 |
| Day's Range | 77.50 - 77.50 |
| 52-Week Range | 65.50 - 89.50 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 30, 2026 |
About IRADIMED CORPORATION
IRADIMED CORPORATION develops, manufactures, markets, and distributes magnetic resonance imaging (MRI) compatible intravenous infusion pump systems and MRI compatible patient vital signs monitoring systems and related accessories. The company offers MRidium 3870 and 3860+ MRI Compatible IV Infusion Pump System with associated disposable IV tubing sets; 3880 MRI compatible patient vital signs monitoring system; and 3600 FMD1 with remote alarm logging unit ferromagnetic detection device. It also provides non-magnetic IV poles, wireless remote dis... [Read more]
Financial Performance
In 2025, IRADIMED CORPORATION's revenue was $83.81 million, an increase of 14.43% compared to the previous year's $73.24 million. Earnings were $22.48 million, an increase of 16.88%.
Financial numbers in USD Financial StatementsNews
IRADIMED CORPORATION to Hold Third Quarter 2026 Financial Results Conference Call on October 30, 2026
ORLANDO, Fla., Oct. 23, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2026 third quarter financial results before the market opens on F...
IRADIMED CORPORATION To Participate in the 5th Annual ROTH Healthcare Opportunities Conference
ORLANDO, Fla., Sept. 23, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (“Iradimed”) (NASDAQ: IRMD), a leading provider of innovative magnetic resonance imaging (MRI) compatible medical devices, announ...
iRadimed initiated with a Hold at Needham
Needham initiated coverage of iRadimed (IRMD) with a Hold rating. iRadimed is in the early innings of a next-generation MRI compatible infusion pump product launch, which should help drive what…
IRADIMED CORPORATION Earnings Call Transcript: Q2 2026
Q2 revenue reached $20.5M with strong demand for the new 3870 MRI IV pump, especially quad systems, driving bookings to more than double shipments. Gross margin dipped to 74% due to ramp-up costs but is expected to recover as efficiencies improve. Full-year guidance is reaffirmed.
IRADIMED CORPORATION Earnings release: Q2 2026
IRADIMED CORPORATION released its Q2 2026 earnings on July 31, 2026, summarizing the period's financial results.
IRADIMED CORPORATION Quarterly report: Q2 2026
IRADIMED CORPORATION has published its Q2 2026 quarterly earnings report on July 31, 2026.
IRADIMED CORPORATION Reports Second Quarter 2026 Financial Results
Announces Regular Quarterly Cash Dividend of $0.20 Per Share Reaffirms Full-Year 2026 Revenue and Earnings Guidance Reports revenue of $20.5 million for the second quarter of 2026, which increased by...
IRADIMED CORPORATION to Hold Second Quarter 2026 Financial Results Conference Call on July 31, 2026
ORLANDO, Fla., July 24, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2026 second quarter financial results before the market opens on ...
IRADIMED CORPORATION to Present at the Goldman Sachs 47th Annual Global Healthcare Conference
ORLANDO, Fla., May 20, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD), a leader in developing innovative MRI-compatible medical devices, today announced that Roger Susi, President and Ch...
IRADIMED CORPORATION Earnings Call Transcript: Q1 2026
Q2 2025 delivered record revenue and earnings growth, driven by strong pump and monitor sales, robust margins, and a record backlog. FDA clearance of the new MRidium 3870 pump sets the stage for accelerated growth and a raised 2025 outlook.
IRADIMED CORPORATION Earnings release: Q1 2026
IRADIMED CORPORATION released its Q1 2026 earnings on May 1, 2026, summarizing the period's financial results.
IRADIMED CORPORATION Quarterly report: Q1 2026
IRADIMED CORPORATION has published its Q1 2026 quarterly earnings report on May 1, 2026.
IRADIMED CORPORATION Reports First Quarter 2026 Financial Results
Announces Regular Quarterly Cash Dividend of $0.20 Per Share Reaffirms Full-Year 2026 Revenue and Earnings Guidance Reports revenue of $22.0 million for the first quarter of 2026, an increase of $2.5...
IRADIMED CORPORATION Proxy statement: Proxy filing
IRADIMED CORPORATION filed a proxy statement on April 30, 2026, providing details for shareholder voting and corporate governance matters.
IRADIMED CORPORATION to Hold First Quarter 2026 Financial Results Conference Call on May 1, 2026
ORLANDO, Fla., April 27, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2026 first quarter financial results before the market opens on ...
IRADIMED CORPORATION to Participate at the 25th Annual Needham Virtual Healthcare Conference
ORLANDO, Fla., April 10, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) today announced that it will participate in the 25th Annual Needham Virtual Healthcare Conference.
iRadimed initiated with a Buy at Freedom Broker
Freedom Broker initiated coverage of iRadimed (IRMD) with a Buy rating and $116 price target The profitable, dividend-paying iRadimed “appears to be the only company” that offers both a nonmagnetic…
IRADIMED CORPORATION to Participate at the 38th Annual Roth Conference
ORLANDO, Fla., March 16, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (NASDAQ: IRMD) today announced that it will participate in the 38 th Annual Roth Conference.
iRadimed price target raised to $120 from $100 at Lake Street
Lake Street raised the firm’s price target on iRadimed (IRMD) to $120 from $100 and keeps a Buy rating on the shares after “another beat” in Q4. The firm continues…
iRadimed price target raised to $120 from $98 at Roth Capital
Roth Capital raised the firm’s price target on iRadimed (IRMD) to $120 from $98 and keeps a Buy rating on the shares following “strong” Q4 results. The firm cited higher…
IRADIMED CORPORATION Earnings Call Transcript: Q4 2025
Q4 2025 revenue rose 17% year-over-year to $22.7 million, with strong growth across all product lines and robust gross margins. The new 3870 pump launch is set to drive significant revenue growth in 2026, supported by positive early feedback and a large replacement market opportunity.
IRADIMED CORPORATION Annual report: Q4 2025
IRADIMED CORPORATION has published its Q4 2025 annual report on February 10, 2026.
IRADIMED CORPORATION Earnings release: Q4 2025
IRADIMED CORPORATION released its Q4 2025 earnings on February 10, 2026, summarizing the period's financial results.
IRADIMED CORPORATION Reports Record Fourth Quarter and Full Year of 2025 Financial Results and Increases its Regular Quarterly Cash Dividend to $0.20 Per Share from $0.17 Per Share
ORLANDO, Fla., Feb. 10, 2026 (GLOBE NEWSWIRE) -- IRADIMED CORPORATION (the “Company” or “Iradimed”) (NASDAQ: IRMD) announced today its financial results for the quarter and year ended December 31, 202...
iRadimed board approves special cash dividend of 50c per share
iRadimed (IRMD) Corporation Board of Directors approved a special cash dividend of $0.50 per share of the Company’s outstanding common stock. This special cash dividend is payable on December 30,…